PARD3
Overview
PARD3 (Partitioning defective 3 homolog) is a cell polarity scaffold protein and novel candidate tumor suppressor identified in aggressive cutaneous squamous cell carcinoma (cSCC). It was mutated in 30.8% of an aggressive cSCC cohort, with one third of mutations predicted to truncate or eliminate the protein.
Alterations observed in the corpus
- Mutated in 30.8% (12/39) of aggressive cSCC cases; novel candidate tumor suppressor; 33% of mutations predicted to truncate/eliminate the protein; significant by driver-detection methods PMID:25303977
Cancer types (linked)
- CSCC: 30.8% mutation rate in aggressive cases; functional role in cSCC requires experimental validation PMID:25303977
Co-occurrence and mutual exclusivity
- Co-occurs with TP53, CDKN2A, NOTCH1, NOTCH2, and other cSCC drivers in the same cohort PMID:25303977
Therapeutic relevance
- No targeted therapies established; functional validation required before therapeutic targeting is feasible PMID:25303977
Open questions
- Functional role of PARD3 as a tumor suppressor in cSCC requires experimental validation; mouse NOTCH2 knockouts are not predisposed to tumors, complicating interpretation of related polarity-pathway members PMID:25303977
Sources
This page was processed by entity-page-writer on 2026-05-11.